SEPN (septerna.com) Market Value to Book Value Ratio

Official company branding of Septerna, Inc. (SEPN)

Septerna Inc (SEPN) leverages advanced molecular engineering to create oral analogs of injectable drugs through a unique analysis of cellular receptors. The current stage is characterized by a lack of mass sales and rising costs as research expands, where the indicator stands at 4.91. This price chart on GURU.Markets, which illustrates trading dynamics, complements data regarding a refined drug delivery system and diversified raw material procurement.

SEPN Septerna Pharma: Market Value to Book Value in the range 11/22/2024 - 10/27/2026
Original product of Septerna Corp

The aggressive development of the Septerna Inc. (SEPN) R&D pipeline based on the Native Complex platform makes the market value-to-book value ratio on GURU.Markets a key indicator of market expectations for future discoveries. This metric, calculated as the ratio of market capitalization to equity, allows for a comparison of the current valuation against the historical median, revealing speculative deviations or hidden balance sheet vulnerabilities in high-risk biotech assets.

Main competitors

Market Value to Book Value Ratio argenx SE|BNTX (biontech.de) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value AbCellera Biologics (ABCL)|Market Capitalization to Book Value Ratio TRML|Precigen Corp - Market Capitalization to Book Value|PHAR: Market Value to Book Value Ratio|NKTR: Market Cap to Net Assets Ratio|UPB (Upstream Bio) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|IMNM (Immunome Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio GOSS|Market Value to Book Value Ratio KalVista Pharmaceuticals KALV|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Rigel Pharma - Market-to-Book Ratio|Market Value to Book Value Ratio ANAB (AnaptysBio Corp)|ATXS - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio ENGN|RAPT (rapt.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Aerovate Therapeutics, Inc. JBIO|Market Capitalization to Net Assets Aclaris Therapeutics Inc. (ACRS)|Market Cap to Net Assets Ratio Kyverna|Market Cap to Book Value Multiple Tiziana Life Sciences, Ltd. (TLSA)|CABA: Market Capitalization to Book Value Ratio|ventyxbio.com - Market-to-Book Ratio|Market Value to Book Value Ratio Theratechnologies (THTX)|AVTX: Market Value to Book Value|Market Value to Book Value Ratio Eledon|Agenus, Inc (AGEN) - Capitalization to Book Value Ratio|CLYM (Climb Bio Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio zurabio.com (ZURA)|aTyr Pharma (ATYR) - Market Cap to Net Assets Ratio|Market Value to Book Value adagene.com (ADAG)|Market Capitalization to Book Value Ratio IMA|Shattuck Labs Inc - Market Capitalization to Book Value|Equillium Bio (EQ) - Market Value to Book Value Ratio|CNTB - Capitalization to Book Value Ratio|IMUX (immunic-therapeutics.com) - Market Capitalization to Book Value Ratio|ATRA (Atara Bio) - Market Cap to Net Assets Ratio|IFRX: Market Value to Book Value Ratio|Market Capitalization to Book Value X4 Pharmaceuticals, Inc|Adicet Bio - Market Capitalization to Book Value Ratio|Market-to-Book Ratio CELU (celularity.com)|INmune Bio (INMB) - Market Value to Book Value Ratio|Barinthus Biotherapeutics PLC - Market Capitalization to Net Assets|Kezar Life Sciences, Inc (KZR) - Market Value to Book Value Ratio|SABS: Capitalization to Book Value Ratio|Market Value to Book Value Ratio Akari Therapeutics (AKTX)|Enlivex Therapeutics Ltd. (ENLV) - Market Capitalization to Net Assets|QTTB - Market Capitalization to Book Value Ratio|Market Value to Book Value GeoVax Labs|Market Capitalization to Book Value Ratio EDSA|Market Capitalization to Book Value Ratio IBIO (iBio Corporation)|Market Value to Book Value Ratio Carisma Therapeutics Inc.|xtlbio.com - Market Value to Book Value|BOLT: Market Value to Book Value Ratio|HCWB - Market Cap to Net Assets Ratio|APVO: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio aimimmuno.com|ADTX - Market Cap to Net Assets Ratio|Market Value to Book Value gribio.com|XRTX (XORTX Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value HIND (Vyome Holdings Inc.)|Revelation Bio - Market Value to Book Value Ratio|Indaptus Corp - Market Cap to Net Assets Ratio|SCNI: Market Value to Book Value Ratio|CalciMedica, Inc. (CALI) - Market Cap to Net Assets Ratio|AFMD: Market Cap to Net Assets Ratio|ALLK (Allakos) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio HOOKIPA Pharma, Inc. (HOOK)|Capitalization to Book Value Ratio IGM Bio|iTeos Therapeutics - Market Capitalization to Book Value Ratio|Market-to-Book Ratio OCEA (oceanbiomedical.com)|Market Value to Book Value Ratio TCBP|Market Capitalization to Book Value Third Harmonic Bio Inc. THRD